These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

877 related articles for article (PubMed ID: 21956446)

  • 1. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.
    Moghaddam B; Javitt D
    Neuropsychopharmacology; 2012 Jan; 37(1):4-15. PubMed ID: 21956446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.
    Okubo R; Okada M; Motomura E
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
    Menniti FS; Lindsley CW; Conn PJ; Pandit J; Zagouras P; Volkmann RA
    Curr Top Med Chem; 2013; 13(1):26-54. PubMed ID: 23409764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
    Kantrowitz JT; Javitt DC
    Brain Res Bull; 2010 Sep; 83(3-4):108-21. PubMed ID: 20417696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.
    Wierońska JM; Pilc A
    Neurochem Int; 2009; 55(1-3):85-97. PubMed ID: 19428811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic aspects of schizophrenia.
    Tamminga C
    Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
    Noetzel MJ; Jones CK; Conn PJ
    Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission.
    Hui C; Wardwell B; Tsai GE
    Recent Pat CNS Drug Discov; 2009 Nov; 4(3):220-38. PubMed ID: 19891601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
    Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G
    Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamatergic theories of schizophrenia.
    Javitt DC
    Isr J Psychiatry Relat Sci; 2010; 47(1):4-16. PubMed ID: 20686195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia.
    Deakin FW; Simpson MD; Slater P; Hellewell JS
    J Psychopharmacol; 1997; 11(2):133-42. PubMed ID: 9254279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
    Moghaddam B; Krystal JH
    Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
    Stone JM
    Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.